A strategy to generate splenic CD11b MutuDC lines is currently underway, which consists in crossing the CD11c-SV40LgT-TG mice to BATF3-deficient mice, which lack the CD8α+ DC subset, potentially resulting in the development of DC tumors of the CD11b subtype. The gene discussed is BATF3; the disease is dyskeratosis congenita.